The pro-oncogenic adaptor CIN85 acts as an inhibitory binding partner of hypoxia-inducible factor prolyl hydroxylase 2.

The EGFR-adaptor protein CIN85 has been shown to promote breast cancer malignancy and hypoxia-inducible factor (HIF) stability. However, the mechanisms underlying cancer promotion remain ill-defined. Here we show that CIN85 is a novel binding partner of the main HIF-prolyl hydroxylase PHD2, but not of PHD1 or PHD3. Mechanistically, the N-terminal SH3 domains of CIN85 interacted with the proline-arginine rich region within the N-terminus of PHD2, thereby inhibiting PHD2 activity and HIF-degradation. This activity is essential in vivo, as specific loss of the CIN85-PHD2 interaction in CRISPR/Cas9 edited cells affected growth and migration properties as well as tumor growth in mice. Overall, we discovered a previously unrecognized tumor growth checkpoint that is regulated by CIN85-PHD2 and uncovered an essential survival function in tumor cells by linking growth factor adaptors with hypoxia signaling.

[1]  M. Shoukier,et al.  Germline deletion of CIN85 in humans with X chromosome–linked antibody deficiency , 2018, The Journal of experimental medicine.

[2]  I. Landrieu,et al.  Structural basis for oxygen degradation domain selectivity of the HIF prolyl hydroxylases , 2016, Nature Communications.

[3]  I. Miinalainen,et al.  Mitochondrial Dysfunction Due to Lack of Manganese Superoxide Dismutase Promotes Hepatocarcinogenesis , 2015, Antioxidants & redox signaling.

[4]  S. Knapp,et al.  Differential Recognition Preferences of the Three Src Homology 3 (SH3) Domains from the Adaptor CD2-associated Protein (CD2AP) and Direct Association with Ras and Rab Interactor 3 (RIN3)* , 2015, The Journal of Biological Chemistry.

[5]  W. Jia,et al.  RHOBTB3 promotes proteasomal degradation of HIFα through facilitating hydroxylation and suppresses the Warburg effect , 2015, Cell Research.

[6]  S. Cascio,et al.  Complex of MUC1, CIN85 and Cbl in Colon Cancer Progression and Metastasis , 2015, Cancers.

[7]  Wei Zhang,et al.  Clinicopathological significance and potential drug target of RUNX3 in breast cancer , 2014, Drug design, development and therapy.

[8]  S. Bae,et al.  RUNX3 inhibits hypoxia-inducible factor-1α protein stability by interacting with prolyl hydroxylases in gastric cancer cells , 2014, Oncogene.

[9]  J. Bravo,et al.  Multimeric and differential binding of CIN85/CD2AP with two atypical proline‐rich sequences from CD2 and Cbl‐b* , 2013, The FEBS journal.

[10]  N. Gotoh,et al.  Adaptor protein complex of FRS2β and CIN85/CD2AP provides a novel mechanism for ErbB2/HER2 protein downregulation , 2013, Cancer science.

[11]  S. Master,et al.  Prolyl Hydroxylase Domain Protein 2 (PHD2) Binds a Pro-Xaa-Leu-Glu Motif, Linking It to the Heat Shock Protein 90 Pathway* , 2013, The Journal of Biological Chemistry.

[12]  R. Depping,et al.  Oxygen sensing by the prolyl-4-hydroxylase PHD2 within the nuclear compartment and the influence of compartmentalisation on HIF-1 signalling , 2012, Journal of Cell Science.

[13]  T. Kietzmann,et al.  Increased levels of the HER1 adaptor protein Rukl/CIN85 contribute to breast cancer malignancy. , 2012, Carcinogenesis.

[14]  G. Semenza.  Molecular mechanisms mediating metastasis of hypoxic breast cancer cells. , 2012, Trends in molecular medicine.

[15]  T. Kietzmann,et al.  GSK-3β regulates cell growth, migration, and angiogenesis via Fbw7 and USP28-dependent degradation of HIF-1α. , 2012, Blood.

[16]  Tyson V. Sharp,et al.  The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to repress HIF-1 activity , 2012, Nature Cell Biology.

[17]  Cai-yun Zhou,et al.  Significance of PTPRZ1 and CIN85 expression in cervical carcinoma , 2011, Archives of Gynecology and Obstetrics.

[18]  K. Akashi,et al.  A critical role of c-Cbl-interacting protein of 85 kDa in the development and progression of head and neck squamous cell carcinomas through the ras-ERK pathway. , 2010, Neoplasia.

[19]  M. McNiven,et al.  A Dyn2–CIN85 complex mediates degradative traffic of the EGFR by regulation of late endosomal budding , 2010, The EMBO journal.

[20]  V. Buchman,et al.  Emerging Roles of Ruk/CIN85 in Vesicle‐Mediated Transport, Adhesion, Migration and Malignancy , 2010, Traffic.

[21]  E. Dimova,et al.  The adaptor protein Ruk/CIN85 activates plasminogen activator inhibitor-1 (PAI-1) expression via hypoxia-inducible factor-1α , 2010, Thrombosis and Haemostasis.

[22]  P. Hasgall,et al.  Hypoxia-inducible Factor Prolyl-4-hydroxylase PHD2 Protein Abundance Depends on Integral Membrane Anchoring of FKBP38* , 2009, The Journal of Biological Chemistry.

[23]  J. Ladbury,et al.  Novel insights into the mechanisms of CIN85 SH3 domains binding to Cbl proteins: solution-based investigations and in vivo implications. , 2009, Journal of molecular biology.

[24]  S. Colla,et al.  The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis. , 2007, Blood.

[25]  K. Kivirikko,et al.  An Endoplasmic Reticulum Transmembrane Prolyl 4-Hydroxylase Is Induced by Hypoxia and Acts on Hypoxia-inducible Factor α* , 2007, Journal of Biological Chemistry.

[26]  P. Toselli,et al.  Structure and function analysis of the CMS/CIN85 protein family identifies actin-bundling properties and heterotypic-complex formation , 2007, Journal of Cell Science.

[27]  Y. Onodera,et al.  CIN85, a Cbl‐interacting protein, is a component of AMAP1‐mediated breast cancer invasion machinery , 2007, The EMBO journal.

[28]  V. Buchman,et al.  Expression of adaptor protein Ruk/CIN85 isoforms in cell lines of various tissue origins and human melanoma. , 2006, Experimental oncology.

[29]  T. Kerppola,et al.  Design and implementation of bimolecular fluorescence complementation (BiFC) assays for the visualization of protein interactions in living cells , 2006, Nature Protocols.

[30]  T. Unterman,et al.  Oxygen-dependent modulation of insulin-like growth factor binding protein biosynthesis in primary cultures of rat hepatocytes. , 2005, Endocrinology.

[31]  E. Yang,et al.  Inhibition of the Catalytic Activity of Hypoxia-Inducible Factor-1α-Prolyl-Hydroxylase 2 by a MYND-Type Zinc Finger , 2005, Molecular Pharmacology.

[32]  P. Bonnier,et al.  Overexpression of hypoxia‐inducible factor HIF‐1α predicts early relapse in breast cancer: Retrospective study in a series of 745 patients , 2005, International journal of cancer.

[33]  A. Ozer,et al.  Regulation of HIF by Prolyl hydroxylases: Recruitment of the Candidate Tumor Suppressor Protein ING4 , 2005, Cell cycle.

[34]  P. Bonnier,et al.  Overexpression of hypoxia-inducible factor HIF-1α predicts early relapse in breast cancer : a retrospective study in a series of 745 patients. , 2005 .

[35]  Tyson V. Sharp,et al.  LIM domains-containing protein 1 (LIMD1), a tumor suppressor encoded at chromosome 3p21.3, binds pRB and represses E2F-driven transcription. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. Harris,et al.  Differential Function of the Prolyl Hydroxylases PHD1, PHD2, and PHD3 in the Regulation of Hypoxia-inducible Factor* , 2004, Journal of Biological Chemistry.

[37]  D. Bredesen,et al.  Atypical Recognition Consensus of CIN85/SETA/Ruk SH3 Domains Revealed by Target-assisted Iterative Screening* , 2003, Journal of Biological Chemistry.

[38]  J. Pouysségur,et al.  HIF prolyl‐hydroxylase 2 is the key oxygen sensor setting low steady‐state levels of HIF‐1α in normoxia , 2003, The EMBO journal.

[39]  K. Kivirikko,et al.  Characterization of the Human Prolyl 4-Hydroxylases That Modify the Hypoxia-inducible Factor* , 2003, Journal of Biological Chemistry.

[40]  Mirko H. H. Schmidt,et al.  SETA/CIN85/Ruk and its binding partner AIP1 associate with diverse cytoskeletal elements, including FAKs, and modulate cell adhesion , 2003, Journal of Cell Science.

[41]  E. Reinherz,et al.  CD2BP3, CIN85 and the structurally related adaptor protein CMS bind to the same CD2 cytoplasmic segment, but elicit divergent functional activities. , 2003, International immunology.

[42]  I. Dikic,et al.  CIN85/CMS family of adaptor molecules , 2002, FEBS letters.

[43]  Mircea Ivan,et al.  Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Giorgio F. Gilestro,et al.  The endophilin–CIN85–Cbl complex mediates ligand-dependent downregulation of c-Met , 2002, Nature.

[45]  I. Dikic,et al.  Cbl–CIN85–endophilin complex mediates ligand-induced downregulation of EGF receptors , 2002, Nature.

[46]  G. Semenza,et al.  HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression , 2001, Molecular and Cellular Biology.

[47]  Michael I. Wilson,et al.  Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.

[48]  R. Birge,et al.  The Adapter Type Protein CMS/CD2AP Binds to the Proto-oncogenic Protein c-Cbl through a Tyrosine Phosphorylation-regulated Src Homology 3 Domain Interaction* , 2001, The Journal of Biological Chemistry.

[49]  L. B. Drobot,et al.  Negative regulation of PI 3‐kinase by Ruk, a novel adaptor protein , 2000, The EMBO journal.

[50]  K. Yamamura,et al.  Recessive mutation in CD2AP causes focal segmental glomerulosclerosis in humans and mice. , 2019, Kidney international.

[51]  P. Ratcliffe,et al.  Regulation of HIF: prolyl hydroxylases. , 2006, Novartis Foundation symposium.